198 related articles for article (PubMed ID: 33135390)
1. Effect of gastric acid-reducing agents on the pharmacokinetics and efficacy of lemborexant.
Landry I; Aluri J; Hall N; Kumar D; Dayal S; Moline M; Reyderman L
Pharmacol Res Perspect; 2020 Dec; 8(6):e00678. PubMed ID: 33135390
[TBL] [Abstract][Full Text] [Related]
2. Pharmacokinetics, Pharmacodynamics, and Safety of the Dual Orexin Receptor Antagonist Lemborexant: Findings From Single-Dose and Multiple-Ascending-Dose Phase 1 Studies in Healthy Adults.
Landry I; Nakai K; Ferry J; Aluri J; Hall N; Lalovic B; Moline ML
Clin Pharmacol Drug Dev; 2021 Feb; 10(2):153-165. PubMed ID: 32468649
[TBL] [Abstract][Full Text] [Related]
3. Effects of Lemborexant on the Pharmacokinetics of Oral Contraceptives: Results From a Phase 1 Drug-Drug Interaction Study in Healthy Females.
Landry I; Aluri J; Hall N; Filippov G; Dayal S; Moline M; Reyderman L
Clin Pharmacol Drug Dev; 2021 Sep; 10(9):1089-1098. PubMed ID: 34107159
[TBL] [Abstract][Full Text] [Related]
4. Evaluation of the CYP3A and CYP2B6 Drug-Drug Interaction Potential of Lemborexant.
Landry I; Aluri J; Nakai K; Hall N; Miyajima Y; Ueno T; Dayal S; Filippov G; Lalovic B; Moline M; Reyderman L
Clin Pharmacol Drug Dev; 2021 Jun; 10(6):681-690. PubMed ID: 33455055
[TBL] [Abstract][Full Text] [Related]
5. Population Pharmacokinetics and Exposure-Response Analyses for the Most Frequent Adverse Events Following Treatment With Lemborexant, an Orexin Receptor Antagonist, in Subjects With Insomnia Disorder.
Lalovic B; Majid O; Aluri J; Landry I; Moline M; Hussein Z
J Clin Pharmacol; 2020 Dec; 60(12):1642-1654. PubMed ID: 32666570
[TBL] [Abstract][Full Text] [Related]
6. Effect of severe renal impairment on pharmacokinetics, safety, and tolerability of lemborexant.
Landry I; Aluri J; Hall N; Filippov G; Dayal S; Moline M; Reyderman L
Pharmacol Res Perspect; 2021 Apr; 9(2):e00734. PubMed ID: 33689224
[TBL] [Abstract][Full Text] [Related]
7. Improvement in fatigue and sleep measures with the dual orexin receptor antagonist lemborexant in adults with insomnia disorder.
Chepke C; Jain R; Rosenberg R; Moline M; Yardley J; Pinner K; Kumar D; Perdomo C; Filippov G; Atkins N; Malhotra M
Postgrad Med; 2022 Apr; 134(3):316-325. PubMed ID: 35254948
[TBL] [Abstract][Full Text] [Related]
8. Physiologically-based pharmacokinetic modeling to predict drug interactions of lemborexant with CYP3A inhibitors.
Ueno T; Miyajima Y; Landry I; Lalovic B; Schuck E
CPT Pharmacometrics Syst Pharmacol; 2021 May; 10(5):455-466. PubMed ID: 33704920
[TBL] [Abstract][Full Text] [Related]
9. Disposition and metabolism of [
Ueno T; Ishida T; Kusano K
Xenobiotica; 2019 Jun; 49(6):688-697. PubMed ID: 29806508
[TBL] [Abstract][Full Text] [Related]
10. Lack of residual morning effects of lemborexant treatment for insomnia: summary of findings across 9 clinical trials.
Moline M; Zammit G; Yardley J; Pinner K; Kumar D; Perdomo C; Cheng JY
Postgrad Med; 2021 Jan; 133(1):71-81. PubMed ID: 33119423
[TBL] [Abstract][Full Text] [Related]
11. Respiratory Safety of Lemborexant in Healthy Subjects: A Single-Dose, Randomized, Double-Blind, Placebo-Controlled, Crossover Study.
Cheng JY; Moline M; Zammit GK; Filippov G; Bsharat M; Hall N
Clin Drug Investig; 2021 May; 41(5):449-457. PubMed ID: 33723806
[TBL] [Abstract][Full Text] [Related]
12. [Preclinical and clinical efficacy of orexin receptor antagonist Lemborexant (Dayvigo
Koebisu M; Koyama N; Nishida M; Muramoto K
Nihon Yakurigaku Zasshi; 2021; 156(2):114-119. PubMed ID: 33642529
[TBL] [Abstract][Full Text] [Related]
13. Effect of hepatic impairment on pharmacokinetics, safety, and tolerability of lemborexant.
Dayal S; Aluri J; Hall N; Filippov G; Moline M; Reyderman L; Landry I
Pharmacol Res Perspect; 2021 Apr; 9(2):e00758. PubMed ID: 33822479
[TBL] [Abstract][Full Text] [Related]
14. Disposition and Metabolism of [
Ueno T; Ishida T; Aluri J; Suzuki M; Beuckmann CT; Kameyama T; Asakura S; Kusano K
Drug Metab Dispos; 2021 Jan; 49(1):31-38. PubMed ID: 33144331
[TBL] [Abstract][Full Text] [Related]
15. Nonclinical evaluation of abuse liability of the dual orexin receptor antagonist lemborexant.
Asakura S; Shiotani M; Gauvin DV; Fujiwara A; Ueno T; Bower N; Beuckmann CT; Moline M
Regul Toxicol Pharmacol; 2021 Dec; 127():105053. PubMed ID: 34619288
[TBL] [Abstract][Full Text] [Related]
16. Lemborexant, A Dual Orexin Receptor Antagonist (DORA) for the Treatment of Insomnia Disorder: Results From a Bayesian, Adaptive, Randomized, Double-Blind, Placebo-Controlled Study.
Murphy P; Moline M; Mayleben D; Rosenberg R; Zammit G; Pinner K; Dhadda S; Hong Q; Giorgi L; Satlin A
J Clin Sleep Med; 2017 Nov; 13(11):1289-1299. PubMed ID: 29065953
[TBL] [Abstract][Full Text] [Related]
17. Pharmacokinetic and pharmacodynamic properties of lafutidine after postprandial oral administration in healthy subjects: comparison with famotidine.
Ikawa K; Shimatani T; Hayato S; Morikawa N; Tazuma S
Biol Pharm Bull; 2007 May; 30(5):1003-6. PubMed ID: 17473452
[TBL] [Abstract][Full Text] [Related]
18. Effect of alcohol coadministration on the pharmacodynamics, pharmacokinetics, and safety of lemborexant: A randomized, placebo-controlled crossover study.
Landry I; Hall N; Aluri J; Filippov G; Setnik B; Dayal S; Reyderman L; Moline M
J Psychopharmacol; 2022 Jun; 36(6):745-755. PubMed ID: 35634694
[TBL] [Abstract][Full Text] [Related]
19. Safety and Efficacy of Lemborexant in Patients With Irregular Sleep-Wake Rhythm Disorder and Alzheimer's Disease Dementia: Results From a Phase 2 Randomized Clinical Trial.
Moline M; Thein S; Bsharat M; Rabbee N; Kemethofer-Waliczky M; Filippov G; Kubota N; Dhadda S
J Prev Alzheimers Dis; 2021; 8(1):7-18. PubMed ID: 33336219
[TBL] [Abstract][Full Text] [Related]
20. Preclinical in vivo characterization of lemborexant (E2006), a novel dual orexin receptor antagonist for sleep/wake regulation.
Beuckmann CT; Ueno T; Nakagawa M; Suzuki M; Akasofu S
Sleep; 2019 Jun; 42(6):. PubMed ID: 30923834
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
